Is the price fair?
What RPRX's price assumes
Royalty Pharma plc trades at 32.2× earnings against 31.5× for the median Biotechnology name, more expensive than its own group.
32.2
Trailing P/E · Biotechnology median 31.5 · 1.02× the median: the market pays up for this one
- Price / sales
- 10.9
Price / sales · as of 2026-Q1
- EV / sales
- 14.3
EV / sales
Details›
- EV / EBIT2026-Q1
- 22.0
- EV / sales2026-Q1
- 14.3
- Healthcare median P/E362 names
- 29.9
- Biotechnology median P/E158 names
- 31.5
- Market capitalisation
- $31.5B
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $27.85 |
| Its own P/E history, median | $38.15 |
| Its own P/E history, upper quartile | $48.42 |
| 52-week range | $34.37 – $63.98 |
| Today | $60.59 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.